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Objectives This study sought to predict the value of tumor marker carbohydrate antigen 125
(CA125) before and after transcatheter aortic valve implantation (TAVI) for all-cause death and a
composite endpoint of death, admission for heart failure, myocardial infarction, and stroke (major
adverse cardiac events [MACE]).
Background Risk stratiﬁcation after TAVI remains challenging. The use of biomarkers in this setting
represents an unmet need.
Methods CA125 was measured in 228 patients before and after TAVI. The association with out-
comes was assessed using parametric Cox regression and joint modeling for baseline and longitudi-
nal analyses, respectively. CA125 was evaluated as logarithm transformation and dichotomized by its
median value (M1 15.7 U/ml vs. M2 15.7 U/ml).
Results At a median follow-up of 183 days (interquartile range: 63 to 365) and 144 days (interquar-
tile range: 56 to 365), 50 patients (22%) died and 75 patients (33%) experienced MACE. A 3-fold in-
crease in the rates for death and MACE was observed in patients above the median (M2 vs. M1) of
CA125 (5.2 vs. 1.6 per 10 person-years and 8.3 vs. 3.3 per 10 person-years, respectively; p for both
0.001). In a multivariable analysis adjusted for logistic EuroSCORE, New York Heart Association
functional class III/IV, and device success, baseline values of CA125 (M2 vs. M1) independently pre-
dicted death (hazard ratio [HR]: 2.18; 95% conﬁdence interval [CI]: 1.11 to 4.26; p  0.023) and
MACE (HR: 1.77; 95% CI: 1.05 to 2.98; p  0.031). In the longitudinal analysis, lnCA125 as a time-
varying exposure, was highly associated with both endpoints: HR: 1.47; 95% CI: 1.01 to 2.14; p 
0.043 and HR: 2.26; 95% CI: 1.28 to 3.98; p  0.005, for death and MACE, respectively.
Conclusions Serum levels of CA125 before and after TAVI independently predict death and MACE. (J Am
Coll Cardiol Intv 2013;6:487–96) © 2013 by the American College of Cardiology Foundation
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488Transcatheter aortic valve implantation (TAVI) is increas-
ingly used as a therapeutic option for patients with symp-
tomatic aortic stenosis and elevated surgical risk. It has been
shown to be superior to medical therapy in patients with
prohibitive elevated risk (1) while being comparable to
conventional surgical aortic valve replacement in high-risk
patients (2).
Due to a high comorbid burden present in this population,
the prediction of outcome after TAVI is very challenging. In
this population, identifying the intrinsic role of the procedure
on outcomes must be dissected from the effect of the associated
comorbidities, progression of comorbid conditions and ele-
vated age. Potentially, biomarkers may play an important role
in this setting. The first studies on the prognostic usefulness of
biomarkers in TAVI have relied on natriuretic peptides.
However, these studies were conducted in a small series of
patients and yielded conflicting results (3–5).
Tumor marker carbohydrate antigen 125 (CA125) is an
emerging cardiac biomarker. In heart failure (HF), CA125 has
shown to be elevated and is re-
leased by mesothelial cells as a
response to serosal effusions and
inflammation (6,7). It has been
shown that CA125 is strongly re-
lated to HF severity and adverse
outcomes in HF (8–10). Re-
cently, in the setting of aortic ste-
nosis, elevated levels of CA125
have also shown to be associated
with disease severity and adverse
outcomes (11). To date, however,
there are no data on the prognos-
tic value of CA125 after TAVI.
We hypothesized that CA125,
as a baseline measurement, might
be a useful prognostic biomarker in patients undergoing
TAVI. Additionally, and more importantly, we hypothe-
sized that changes in CA125 after TAVI might be strongly
indicative of adverse outcomes following TAVI. As such,
the aim of this study was 2-fold: 1) to evaluate the
prognostic significance of pre-procedural values of CA125;
and 2) to determine whether repeated measurements of
CA125 after TAVI remain indicative of elevated risk.
Methods
Patients and indications. We included 228 consecutive pa-
ients undergoing TAVI in our institution. TAVI was
erformed due to degenerative calcified native aortic steno-
is in 211 cases (93%), degenerated bioprostheses in 13 cases
6%), and severe aortic regurgitation in 4 cases (2%). An
nterdisciplinary heart team discussed all cases, and consen-
us was reached regarding the best therapeutic strategy in
Abbreviations
and Acronyms
CI  confidence interval
HF  heart failure
HR  hazard ratio
JM  Joint Modeling
MACE  major adverse
cardiac events
NT-proBNP  N-terminal pro–
B-type natriuretic peptide
NYHA  New York Heart
Association
TAVI  transcatheter aortic
valve implantationach individual case. The local ethics committee approvedhe study protocol, and all patients provided written in-
ormed consent to participate in a clinical registry.
Description of the TAVI procedures. TAVI was performed
either via the transfemoral approach (n  137) using a
alloon expandable (SAPIEN XT, Edwards Lifesciences,
rvine, California, n  79) or a self-expandable prosthesis
CoreValve, Medtronic, Irvine, California, n  58) or by
he transapical approach (n  89) using a balloon expand-
ble prosthesis (SAPIEN XT, Edwards Lifesciences). In 2
ases, a different access route was used (subclavian and direct
ortic). Access route was dichotomized as “transfemoral”
ersus “non-transfemoral.” TAVI procedures were per-
ormed in the catheterization laboratory or the hybrid
perating suite under general anesthesia. TAVI operators
ere unaware of CA125 values.
Laboratory analyses and CA125 measurement. CA125 was
determined from routine blood samples using a chemilumi-
nometric immunoassay (ADVIA Centaur, Siemens Health-
care, Erlangen, Germany) at least 24 h before TAVI and on
follow-up visits. Blood samples were measured and analyzed
immediately. The manufacturer’s cutoff value for a patho-
logical test result is 30 U/ml.
Follow-up and deﬁnition of outcomes. All data were pro-
spectively collected. Two cardiologists and 3 trained nurses,
unaware of CA125 values, were in charge of patients’
follow-up. Scheduled visits took place on a 3-month basis
during outpatients’ clinic visits, telephone interviews with
the patient or his/her family, or by reviewing the patient’s
hospital record. Patients were scheduled at the outpatient
clinic (at least 1 to 3 and 6 to 12 months after TAVI) for
clinical and echocardiographic examinations as well as blood
sampling.
The endpoints of this study were all-cause death and
major adverse cardiac events (MACE) defined as a com-
posite of all-cause death, acute HF requiring admission,
myocardial infarction, and stroke, whichever occurred first
during follow-up. Procedure-related death, but not other
procedural complications, were included into MACE. To
adjudicate an event, consensus between the 2 cardiologists
was required.
Thirty-day mortality was defined as death from any cause
during the first 30 days after the procedure or as intrahos-
pital death after the TAVI procedure. Procedural success
was defined using the following criteria: successful vascular
access, delivery, and deployment of the device with success-
ful retrieval of the delivery system, correct position of the
device in the proper anatomical location with adequate
performance, and the patient leaving the operating theater
alive. Device success and procedural complications were
categorized using criteria defined by the Valve Academic
Research Consortium (12). In short, device success was
defined as procedural success with a correct position and
function of the prosthesis (less than grade 2 residual aortic
regurgitation) and only 1 valve implanted per patient (12).
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489Statistical analysis. Continuous variables were expressed as a
ean SD or as the median (interquartile range) and using
he unpaired Student t test or Mann-Whitney U test as
ppropriate. Discrete variables were compared with the
hi-square test or Fisher exact test as appropriate. Outcome
ates were depicted among the populations according to the
edian and manufacturer’s cutoff value (30 U/ml) of
A125 using the Kaplan-Meier method and compared
ith the log-rank test.
BASELINE ANALYSIS. A multivariable time-to-event analysis
as performed using a flexible parametric survival analysis
13). For this analysis, our primary exposure was CA125
ontinuous (transformed by its logarithm, lnCA125); how-
ver, we also tested for the prognostic effect of CA125,
ither dichotomized according to the median (M2 vs. M1)
r according to the manufacturer’s cutoff value (30 U/ml).
aseline covariates were chosen based on scientific knowl-
dge, regardless of their p value in the univariate analysis.
he final baseline model included logistic EuroSCORE,
ew York Heart Association (NYHA) functional class
II/IV, and device success as covariates. The model’s dis-
rimination and calibration was assessed by the Harrell’s C
tatistic and the Hosmer–Lemeshow test, respectively.
LONGITUDINAL ANALYSIS. In order to test whether longi-
tudinal measures of CA125 better discriminate those pa-
tients with a higher likelihood of adverse outcomes, CA125
levels (and other relevant prognostic factors) were collected
before TAVI (baseline) and every 3 months afterward until
last time point of event-free follow-up or the date of death
(or MACE). Apart from CA125, those prognostic factors
that were missing during follow-up, and thus could not be
used as time-varying variables, were included in the models
using the respective baseline values. To account for the fact
that our study includes a repeated-measures design with a
survival endpoint, we used a Joint Modeling (JM) approach.
This is a family of methods that has been developed to
explicitly account for the dependence between the longitu-
dinal change of a continuous exposure and event time data
(14). The benefits of the joint modeling approach compared
with the traditional Cox regression models is the fact that it
accounts for the measurement error (i.e., biological varia-
tion) and the informative dropout in CA125, and that it can
give more efficient results (i.e., smaller standard errors) by
combining information from the longitudinal and survival
outcomes (15). Joint models of this type combine a linear
mixed effect that describes the longitudinal trajectory of a
continuous exposure, with a proportional hazards model for
the time-to-event. In the former model, covariates and
random terms (random intercepts and random slopes) are
selected using a likelihood-ratio test. In the latter model, the
fitted exposure trajectory is related to the hazard for event
through a parametric Cox analysis.
In order to determine how longitudinally updated values
of CA125 relate with the hazard for death or MACE, we Umodeled its natural logarithm within a linear mixed regres-
sion framework that include random intercept and slopes
(heretofore called the longitudinal submodel). N-terminal
pro–B-type natriuretic peptide (NT-proBNP) (transformed
by its natural logarithm) was added as a time-varying
covariate. Time (in weeks) was included as a random effect
and modeled with a polynomial of power 1. Sex, logistic
EuroSCORE of 20%, and left ventricular ejection fraction
(%) were included as time-constant covariates (with their
respective baseline values).
In the survival approach (heretofore called the survival
submodel), the predicted time-history of lnCA125 from the
linear mixed model was related to the hazard for death or
MACE through a time-varying parametric Cox. Here, the
hazard function was modeled with restricted cubic splines.
The final model included lnNT-proBNP as a time-varying
covariate, whereas the logistic EuroSCORE, device success
and NYHA functional class III/IV were included as time-
constant covariates.
The survival estimates are presented as hazard ratios
(HR) with the 95% confidence intervals (CI).
A 2-sided p value of 0.05 was considered statistically
significant for all analyses. Baseline analyses were carried-
out using Stata (StataCorp, Stata Statistical Software Re-
lease 12, College Station, Texas). The longitudinal analyses
were performed with the statistical module JM (16) in R (R
Foundation for Statistical Computing, Vienna, Austria).
Results
The baseline clinical, echocardiographic, and laboratory
characteristics of the entire study population are displayed in
Table 1. TAVI was successfully performed in 221 patients
(97%) with device success achieved in 196 cases (86%).
Procedural mortality was 2% (5 of 228), and the overall
30-day mortality was 7% (15 of 228). The procedural data
and complications are depicted in Table 2.
During a median follow-up of 183 days [interquartile
range: 63 to 365], in total, 50 patients (22%) died. MACE
occurred in 75 patients (33%: death [n  42], admissions
for acute heart failure [n  28], stroke [n  4], and
yocardial infarction [n 1]) during a median follow-up of
44 [56 to 365] days. The clinical, laboratory, and echocar-
iographic characteristics at baseline according to all-cause
eath and MACE are presented in Table 1.
Baseline CA125 and adverse outcome after TAVI. The clin-
ical, laboratory, echocardiographic and procedural charac-
teristics of the patients at baseline were stratified according to
the median of CA125, and are presented in Tables 3 and 4.
edian pre-procedural CA125 was higher in patients who
ied (28 U/ml [15 to 51] vs. 12 U/ml [8 to 29]; p  0.001)
nd who experienced MACE (23 U/ml [9 to 28] vs. 14
/ml [9 to 28]; p  0.003).
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490An approximate 3-fold increase in the rate of death and
MACE was observed in patients with elevated baseline
CA125 (M2  5.2 vs. M1  1.6 per 10 persons-year and
M2  8.3 vs. M1  3.3, respectively; p for both 0.001)
nd for CA125 30 U/ml versus CA125 30: 6.1 versus
.3 per 10 persons-year and 9.5 versus 4.2 per 10 persons-
ear, respectively; p for both 0.001). These differences
Table 1. Baseline Clinical and Echocardiographic Characteristics for the E
Variables
All Patients
(N  228)
All-Cause Dea
No
(n  178)
Clinical characteristics
Age, yrs 79 6 79 6
Male 124 (54) 99 (56)
Logistic EuroSCORE 16 [9–23] 14 [9–21]
Access TF vs. non-TF 137/91 110/68
Body mass index, kg/m2 27 4 27 4
Diabetes 81 (36) 63 (35)
Hypertension 145 (64) 117 (66)
Hypercholesterolemia 57 (25) 43 (24)
Atrial ﬁbrillation 79 (35) 55 (31)
Previous SAVR 13 (6) 9 (5)
Previous CABG 32 (14) 24 (14)
Previous CAD 87 (38) 66 (37)
Previous PCI 51 (22) 43 (24)
Previous malignoma 29 (13) 24 (14)
Previous MI 16 (7) 12 (7)
Previous stroke* 25 (11) 22 (12)
Renal failure† 66 (29) 43 (24)
COPD‡ 36 (16) 22 (12)
Peripheral arteriopathy 41 (18) 31 (17)
Pacemaker 26 (11) 17 (10)
Previous dialysis 11 (5) 7 (4)
NYHA functional class III/IV 190 (83) 141 (79)
Laboratory
Hemoglobin, g/dl 12.2 1.8 12.3 1.8
Creatinine, mg/dl 1.44 0.9 1.35 1.04
CA125, U/ml 17 [9–40] 12 [8–29]
NT-proBNP, pg/ml 2,103 [748–5,381] 1,727 [616–4,384] 4,32
Echocardiography
LVEF 50% 179 (79) 145 (82)
LVEF 40%–49% 35 (15) 21 (12)
LVEF 40% 14 (6) 12 (7)
Mean gradient, mm Hg 48 17 49 18
Maximal gradient, mm Hg 80 28 81 30
PAH§ 24 (11) 13 (7)
Aortic valve area, cm2 0.7 [0.6–0.8] 0.7 [0.6–0.8] 0
Values are mean SD, n (%), or median [interquartile range]. *Severely affecting ambulation or da
§Pulmonary artery pressure60 mm Hg.
CABGcoronaryarterybypassgraft;CADcoronaryarterydisease;COPDchronicobstructivepulm
infarction;NT-proBNPN-terminalpro–B-typenatriureticpeptide;NYHANewYorkHeartAssociation;
replacement; TF transfemoral.ere consistent along the entire follow-up. Using the (aplan-Meier method, the cumulative event rates for all-
ause death and MACE are displayed in Figures 1 and 2
nd in Online Figures 1 and 2.
In the multivariate analysis, after adjusting for the logistic
uroSCORE, NYHA functional class III/IV and device
uccess, baseline CA125 (M2 vs. M1) remained indepen-
ently associated with an increased risk of all-cause death
opulation and According to All-Cause Death and MACE
p Value
MACE
p Value
s
50)
No
(n  153)
Yes
(n  75)
6 0.087 79 6 79 6 0.793
50) 0.481 87 (57) 37 (49) 0.284
26] 0.016 14 [8–21] 18 [11–26] 0.159
23 0.320 96/57 41/34 0.242
4 0.179 27 4 27 4 0.777
36) 0.937 50 (33) 31 (41) 0.200
56) 0.206 99 (65) 46 (61) 0.619
28) 0.579 37 (24) 20 (27) 0.684
48) 0.025 47 (31) 32 (43) 0.075
8) 0.428 8 (5) 5 (7) 0.660
16) 0.651 17 (11) 15 (20) 0.069
42) 0.527 55 (36) 32 (43) 0.326
16) 0.221 35 (23) 16 (21) 0.793
10) 0.514 20 (13) 9 (12) 0.819
8) 0.758 9 (6) 7 (9) 0.338
6) 0.203 16 (11) 9 (12) 0.726
46) 0.003 36 (24) 30 (40) 0.010
28) 0.007 20 (13) 16 (21) 0.108
20) 0.674 29 (19) 12 (16) 0.585
18) 0.097 14 (9) 12 (16) 0.126
8) 0.236 5 (3) 6 (8) 0.117
98) 0.002 118 (77) 72 (96) 0.001
1.6 0.173 12.2 1.8 12.2 1.8 0.973
1.36 0.033 1.28 0.9 1.76 0.2 0.008
51] 0.001 14 [9–28] 23 [13–52] 0.003
50–8,806] 0.007 1,699 [566–4,148] 3,601 [1,352–8,681] 0.011
68) 0.018 128 (84) 51 (68) 0.026
28) 18 (12) 17 (23)
4) 7 (5) 7 (9)
12 0.098 50 18 43 14 0.003
19 0.202 83 29 73 24 0.014
22) 0.006 13 (9) 11 (15) 0.151
–0.9] 0.979 0.7 [0.6–0.8] 0.7 [0.6–0.9] 0.712
y functioning. †Serum creatinine200 mol/l. ‡On long-term use of bronchodilators or steroids.
disease; LVEF left ventricularejection fraction;MACEmajoradversecardiacevents;MImyocardial
ulmonaryarterialhypertension;PCIpercutaneouscoronary intervention;SAVRsurgicalaortic valventire P
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491(HR: 1.77; 95% CI: 1.05 to 2.98; p 0.031). Risk estimates
were borderline significant for CA125 30 U/ml, and
nonsignificant for lnCA125 (Table 5). The Harrell’s C
statistics of the multivariate models with and without
CA125 (median) were 0.724 versus 0.697 for all-cause
death and 0.695 versus 0.678 for MACE.
In a sensitivity analysis, in which NT-proBNP (either as
a continuous variable or dichotomized by its median) was
forced into the final model, it was not associated with either
endpoint (Table 5). In such analyses, however, the associ-
ation of CA125 (M2 vs. M1) with the risk of all-cause death
(HR: 2.20; 95% CI: 1.11 to 4.34; p  0.023) and MACE
(HR: 1.78; 95% CI: 1.05 to 3.01; p  0.031) remained
almost unaltered.
Longitudinal analyses. Including baseline measurements,
available measurements of CA125 per patient ranged from
1 to 5 with a median of 2. Of the 228 patients undergoing
TAVI, 69 (30%) had only 1 value (corresponding to
baseline), mainly because of early deaths. In 29% of the
patients (65 of 228), 2 values; in 22% (51 of 228), 3 values;
in 13% (29 of 228), 4 values; and in 6% (14 of 228), 5 values
were available.
The mean observed trajectory for lnCA125 showed no
important fluctuations in patients with no events. In those
Table 2. Intra- and Post-Procedural Data and Complications of the Entire P
Variables
All Patients
(N  228)
All-Cause Deat
No
(n  178) (
Procedural success 221 (97) 175 (98)
Device success 196 (86) 159 (89)
Myocardial infarction 3 (1) 1 (1)
Emergency sternotomy 6 (3) 4 (2)
Procedural time, min 64 [51–84] 62 [50–82] 7
Contrast, ml 88 [58–140] 87 [54–134] 10
Fluoroscopy, min 13 [9–17] 13 [9–17] 1
Major vascular complications 12 (5) 7 (4)
Life-threatening bleeding 20 (9) 14 (8)
Major bleeding 41 (18) 29 (16)
Major stroke 4 (2) 1 (1)
Minor stroke 1 (0.4) 0 (0)
Post-procedural AR (1) 11 (5) 5 (3)
Rethoracotomy 8 (4) 3 (2)
Need for vaECMO 21 (9) 16 (9)
Prophylactic vaECMO 12 (5) 12 (7)
Emergency vaECMO 9 (4) 4 (2)
Need for acute dialysis 22 (10) 6 (3)
Need for pacemaker 32 (16) 23 (14)
Days on ICU 1 [1–2] 1 [1–1]
Days in hospital 9 [7–14] 9 [7–13] 1
Values are n (%) or median [interquartile range].
AR aortic regurgitation; ICU intensive care unit; MACEmajor adverse cardiac events; vaECMwith events, a steady increase in lnCA125 before the occur- prence of death or MACE was observed (Figs. 3A and 3B,
nline Figs. 3 and 4 for natural values of CA125). This
ndicates a positive association between longitudinal re-
ponse and time to death/MACE. Moreover, these patients
tarted the follow-up with higher values of lnCA125.
egression estimates from the JM-longitudinal submodel
re presented in Table 6.
The output from the JM-survival submodel identified
nCA125 as a powerful and independent predictor of both
ndpoints (Table 6). After controlling for lnNT-proBNP
modeled as a time-varying covariate), and baseline values of
he logistic EuroSCORE, NYHA functional class III/IV, and
evice success, we found that for each unit increase in
nCA125, there was a predicted 47% increase for the risk of
eath. For MACE, the predicted increase of risk was even
reater (more than 2-fold) (see Table 6 for the estimates). Of
ote, the regression estimate for lnCA125 did not change
ignificantly after eliminating the nonsignificant variables from
he model (EuroSCORE and lnNT-proBNP).
Two additional sensitivity analyses were performed to
valuate the prognostic significance of CA125 (M2 vs. M1)
nd CA125 (30 vs. 30 U/dl). Here, lnNT-proBNP was
odeled as a time-varying exposure instead of lnCA125. In
he first analysis, CA125 (M2 vs. M1), but not lnNT-
Population and According to All-Cause Death and MACE
p Value
MACE
p Value0)
No
(n  153)
Yes
(n  75)
) 0.022 150 (98) 71 (95) 0.165
) 0.006 138 (90) 58 (77) 0.009
0.059 1 (1) 2 (3) 0.210
0.494 4 (3) 2 (3) 0.982
90] 0.250 60 [50–80] 70 [53–86] 0.051
158] 0.414 80 [52–134] 100 [67–150] 0.062
21] 0.713 13 [9–17] 13 [9–21] 0.846
) 0.142 7 (5) 5 (7) 0.506
) 0.361 14 (9) 6 (8) 0.773
) 0.210 24 (16) 17 (23) 0.197
0.010 0 (0) 4 (5) 0.004
0.059 0 (0) 1 (1) 0.329
) 0.006 4 (3) 7 (10) 0.042
) 0.005 3 (2) 5 (7) 0.070
) 0.827 13 (9) 8 (11) 0.594
0.059 10 (7) 2 (3) 0.219
) 0.013 3 (2) 6 (8) 0.028
) 0.001 3 (2) 19 (25) 0.001
) 0.210 22 (16) 10 (16) 0.973
] 0.001 1 [1–1] 1 [1–4] 0.001
2] 0.037 9 [7–12] 11 [7–18] 0.098
na-arterial extracorporeal membrane oxygenation.atient
h
Yes
n  5
46 (92
37 (74
2 (4)
2 (4)
0 [53–
1 [63–
3 [10–
5 (10
6 (12
12 (24
3 (6)
1 (2)
6 (12
5 (10
5 (10
0 (0)
5 (10
16 (32
9 (23
3 [1–5
3 [7–2roBNP, was independently related to the risk of death (HR:
i
p
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4922.88; 95% CI: 1.43 to 5.80; p  0.003) and MACE (HR:
2.02; 95% CI: 1.19 to 3.43; p  0.010) (Online Table 1). In
the second analysis, the estimates for CA125 (30 vs. U/ml
30 U/ml) did not reach statistical significance for death
(HR: 1.55; 95% CI: 0.83 to 2.90; p  0.167), although it
did for MACE (HR: 1.93; 95% CI: 1.16 to 3.19; p 
0.011). Values of CA12530 U/ml were associated with an
almost 2-fold increase in MACE (HR: 1.93; 95% CI: 1.16
to 3.19; p  0.011) (Online Table 2). In both analyses,
Table 3. Clinical and Echocardiographic Characteristics of the
Entire Patient Population and According to Median CA125
Variables
CA125-M1
(n  108)
CA125-M2
(n  120)
p
Value
Clinical characteristics
Age, yrs 79 5 80 7 0.295
Male 51 (47) 73 (61) 0.039
Logistic EuroSCORE 11 [8–19] 18 [11–27] 0.001
Access TF vs. non-TF 60/48 (56/44) 77/43 (64/43) 0.185
Body mass index, kg/m2 27.3 3.9 26.2 4.0 0.059
Diabetes 38 (35) 43 (36) 0.919
Hypertension 80 (74) 65 (54) 0.002
Hypercholesterolemia 32 (30) 25 (21) 0.126
Atrial ﬁbrillation 30 (28) 49 (41) 0.039
Previous SAVR 2 (2) 11 (9) 0.017
Previous CABG 17 (16) 15 (13) 0.482
Previous CAD 46 (43) 41 (34) 0.191
Previous PCI 31 (29) 20 (17) 0.029
Previous malignoma 19 (18) 10 (8) 0.036
Previous MI 7 (7) 9 (8) 0.764
Previous stroke* 13 (12) 12 (10) 0.623
Renal failure† 23 (21) 43 (36) 0.016
COPD‡ 18 (17) 18 (15) 0.730
Peripheral arteriopathy 25 (23) 16 (13) 0.054
Pacemaker 14 (13) 12 (10) 0.482
Previous dialysis 3 (3) 8 (7) 0.171
NYHA functional class III/IV 74 (69) 116 (97) 0.001
Laboratory
Hemoglobin, g/dl 12.3 1.8 12.1 1.7 0.288
Creatinine, mg/dl 1.27 0.92 1.59 1.27 0.031
NT-proBNP, pg/ml 1,054 [455–2,450] 4,010 [1,575–9,191] 0.001
Echocardiography
LVEF 50% 98 (91) 81 (68) 0.001
LVEF 40%–49% 8 (7) 27 (23)
LVEF 40% 2 (2) 12 (10)
Mean gradient, mm Hg 47 17 49 18 0.315
Maximal gradient, mm Hg 78 28 82 28 0.293
PAH§ 4 (4) 20 (17) 0.004
Aortic valve area, cm2 0.7 [0.7–0.9] 0.7 [0.6–0.8] 0.196
Values are mean SD, n (%), or median [interquartile range]. *Severely affecting ambulation or
day-to-day functioning. †Serum creatinine200 mol/l. ‡On long-term use of bronchodilators
or steroids. §Pulmonary artery pressure60 mm Hg.
CA125-M1  below the median; CA125-M2  above the median; other abbreviations as in
Table 1.lnNT-proBNP, either as a main time-varying exposure or asa time-varying covariate, was not significantly associated
with either endpoint.
Discussion
The present study is the first, to our knowledge, to assess the
prognostic value of CA125 in TAVI. It could be shown that
first, CA125 (modeled as lnCA125) was a strong predictor
of death or MACE in a longitudinal setting. Explicitly,
using JM analysis, serial CA125 measurements after TAVI
were significant predictors of both outcomes, even when
modeled simultaneously with time-varying NT-proBNP,
logistic EuroSCORE, baseline NYHA functional class
III/IV, and device success. Second, patients with elevated
baseline CA125 values (above the median) showed an
independent increase of risk for all-cause death or MACE
after TAVI.
Risk prediction in TAVI. Risk prediction in TAVI is an
mportant research avenue aimed at the identification of those
atients who might benefit most from close follow-up and/or
dditional monitoring after the procedure. However, this is a
hallenging goal, mainly because despite successful TAVI,
atients still remain at high risk for adverse events due to an
xtremely high burden of comorbidity. This issue becomes
vident by a relative high mortality rate during follow-up as has
een reported from randomized trials (17) and registries (18)
Table 4. Intra- and Post-Procedural Data and Complications for the
Entire Population and According to Median CA125
Variables
CA125-M1
(n  108)
CA125-M2
(n  120)
p
Value
Procedural success 106 (98) 115 (96) 0.312
Device success 92 (85) 104 (87) 0.748
Myocardial infarction 1 (1) 2 (2) 0.624
Emergency sternotomy 2 (2) 4 (3) 0.485
Procedural time, min 64 [53–85] 63 [51–82] 0.964
Contrast administration, ml 85 [59–152] 90 [57–130] 0.685
Fluoroscopy, min 13 [9–19] 13 [9–17] 0.941
Major vascular complications 4 (4) 8 (7) 0.317
Life-threatening bleeding 10 (9) 10 (8) 0.805
Major bleeding 16 (15) 25 (21) 0.237
Major stroke 0 (0) 4 (3) 0.124
Minor stroke 0 (0) 1 (1) 0.342
Post-procedural regurgitation, 1 5 (5) 6 (5) 0.885
Rethoracotomy 2 (2) 6 (5) 0.197
Need for vaECMO 5 (5) 16 (13) 0.023
Prophylactic vaECMO 2 (2) 10 (8) 0.029
Emergency vaECMO 3 (3) 6 (5) 0.390
Need for acute dialysis 7 (7) 15 (13) 0.124
Need for permanent pacemaker 15 (16) 17 (16) 0.988
Days on intensive care unit 1 [1–2] 1 [1–2] 0.631
Days in hospital 9 [7–12] 9 [7–14] 0.701
Values are n (%) or median [interquartile range].Abbreviations as in Tables 1 and 2.
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493with a comparable rate of procedural and device success as in
the present study. Thus, in TAVI, there is an unmet need to
discover novel tools to improve the prediction of outcomes and
to discriminate those patients who may benefit the most.
In this way, risk prediction using pre-procedural variables
is the most appealing approach, since it bears the potential
to determinate expected benefit from the procedure and
therefore to allow a more rational treatment allocation.
Several scores, such as the logistic EuroSCORE (19) or the
STS score (20), have been proposed to summarize all
prognostic factors. Biomarkers, in this setting, might be
envisioned, not only as a tool for pre-procedural risk
assessment, but also for monitoring treatment success after
TAVI.
Biomarkers in TAVI. Natriuretic peptides show elevated val-
ues in aortic stenosis, correlate with disease severity, and
have been used to predict symptom-free survival, prognosis,
and post-operative outcome (21–23). As a consequence,
these biomarkers were the first to be studied for risk
prediction in the setting of TAVI (3–5). Nevertheless, these
studies have been conducted in small populations and
short-term follow-up, and have yielded conflicting results.
In our study, although lnNT-proBNP was associated
with death and MACE, we did not find a prognostic value
Figure 2. Cumulative and Crude Event Rate of MACE According to Elevate
To the left, the cumulative rate of major adverse cardiac events (MACE) is dep
Figure 1. Cumulative and Crude Event Rate of All-Cause Death According t
To the left, the cumulative rate of all-cause death is depicted with Kaplan-Mei
catheter aortic valve implantation.shown. TAVI  transcatheter aortic valve implantation.of NT-proBNP when modeled concomitantly with CA125
and other adjusting covariates. This was true for baseline
values as well as in the JM analyses. These negative findings
may be explained by the fact that NT-proBNP has a short
half-life (24) and is therefore of limited use to assess
long-term prognosis. Additionally, the high prevalence of
old age and renal dysfunction in this population may also
explain the limited use of this biomarker in this setting.
Finally, a high correlation found between NT-proBNP
and CA125 (r  0.49) in the present study may also play
a role.
Additionally, periprocedural elevations of cardiac necrosis
markers (e.g., troponin or creatine kinase–myocardial band)
have been associated with an increased mortality and a lesser
degree of improvement of left ventricular ejection fraction
(25). Because we did not perform routine troponin deter-
mination in our present study population, we cannot pro-
vide a comparison of CA125. Emerging evidence, however,
allows us to speculate that most patients who meet the
criteria for TAVI will have pre-procedural troponin deter-
minations within normal limits.
Clinical role of CA125 following TAVI. CA125 is an emerging
iomarker in HF and is released by mesothelial cells in
esponse to the presence of serosal effusions and/or proin-
ls of Pre-Procedural CA125
with Kaplan-Meier method, whereas on the right, the crude MACE rates are
vated CA125
thod, whereas on the right, the crude death rates are shown. TAVI  trans-d Leve
ictedo Ele
er me
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494flammatory cytokines (6). These 2 triggers of CA125 are
pathophysiological mechanisms, which are profoundly re-
lated to the severity and progression of HF (26–28).
Accordingly, previous studies have shown that CA125 is
associated with disease severity and outcome in HF
(8–10,29,30). Moreover, a recent study has shown that
CA125 is also elevated in symptomatic severe aortic stenosis
and correlates with symptom severity and outcomes (11).
Figure 3. Subject-Specific Longitudinal Trajectories of LnCA125
Subject-speciﬁc longitudinal trajectories of LnCA125 for patients who were cen
Time scale is adjusted to each patient’s survival time. A and B display the lon
In patients who were censored and did not reach an endpoint (censored  la
decreasing tendency over time. By contrast, patients who experienced an even
Table 5. Pre-Procedural Estimates of the Association of CA125 and NT-pro
All-Cause Death
Variables HR (95% CI) p Value
lnCA125* 1.15 (0.89–1.50) 0.280
CA125 M2 vs. M1* 2.18 (1.11–4.26) 0.023
CA125 30 U/ml* 1.74 (0.99–1.40) 0.063
lnNT-proBNP† 1.06 (0.84–1.34) 0.607
NT-proBNP median† 1.11 (0.57–2.17) 0.758
Parametric Cox regression analysis was performed, with baseline hazard functionmodeledwith 4 d
class III/IV and device success. †Estimates adjusted by the logistic EuroSCORE, NYHA functional cla
CI confidence interval; HR hazard ratio; other abbreviations as in Tables 1 and 3.major adverse cardiac events.In the present study, elevated CA125 levels before TAVI
and during follow-up were associated with a higher rate of
death and MACE. These effects were independent of
established risk predictors, such as the logistic Euro-
SCORE, NYHA functional class III/IV, or device success.
When compared with NT-proBNP, CA125 showed a clear
superiority as a prognostic biomarker, perhaps due to its
stability and longer half-life (around 7 to 12 days) (31).
or reached an endpoint. Solid lines denote the ﬁt of the loess smoother.
al trajectories across died/censoring or MACE/censoring status, respectively.
tact alive and event-free), CA125 levels remain relatively stable with a slight
A125 levels show an elevation as they get closer to the event. MACE 
nd the Risk of All-Cause Death and MACE
MACE
rell’s C
atistic HR (95% CI) p Value
Harrell’s C
Statistic
.689 1.13 (0.91–1.41) 0.264 0.675
.724 1.77 (1.05–2.98) 0.031 0.695
.695 1.53 (0.95–2.47) 0.078 0.676
.721 1.06 (0.85–1.28) 0.493 0.695
.723 1.10 (0.64–1.90) 0.726 0.693
f freedom restricted cubic splines. *Estimates adjusted by the logistic EuroSCORE, NYHA functional
device success, and CA125 above the median.sored
gitudin
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495Additionally, as a biomarker, CA125 possesses some more
theoretical advantages. First, levels of this biomarker show a
close relationship with HF severity and increased risk of
death and subsequent readmission for acute HF (8–10,28).
Second, it is widely available and less expensive than other
biomarkers. Third, plasma levels do not seem to be rele-
vantly influenced by age, renal function, or body mass index
(8,9). Fourth, evidence from data in patients with acute HF
supports the hypothesis that changes in CA125 over time
are more likely due to changes in disease status than to
biological variation (9,29). Moreover, with a half-life longer
than 1 week, CA125 does not seem to be a marker with
high short-term variability.
These properties advocate CA125 as the ideal biomarker
to monitor the evolution of our elderly TAVI patients.
Despite being a stable biomarker, CA125 has shown tem-
poral trajectories that closely follow the functional status of
the patient, and consequently, discriminates those patients
at high risk for adverse outcomes (29).
Clinical implications. First, baseline CA125 values might be
useful tool for the determination of the optimal time point
or TAVI. Those patients with elevated levels of CA125
ay require a more aggressive treatment before the proce-
ure. Perhaps the subgroup with persistently elevated levels
f CA125 may not benefit at all from the procedure.
Second, our longitudinal results support the potential for
he use of this biomarker for monitoring the clinical
Table 6. Joint Model Regression Estimates
All-C
Longitudinal Submodel for lnCA125* -Coefficient (
Intercept 1.456 (0.908 to 2
lnNT-proBNP† 0.153 (0.092 to 0
LVEF‡ 0.074 (090 to0
Sex 0.224 (0.007 to 0
Time, weeks† 0.091 (0.141 to
Sex*time 0.045 (0.015 to 0
EuroSCORE20‡ 0.130 (0.378 to
EuroSCORE20*time 0.033 (0.001 to 0
All-Cause
Survival Submodel§ HR (95% CI)
lnCA125† 1.47 (1.01 to 2.14)
lnNT-proBNP† 1.06 (0.81 to 1.39)
EuroSCORE‡ 1.48 (1.04 to 2.10)
Device success, 1 vs. 0‡ 0.44 (0.22 to 0.86)
NYHA functional class III/IV‡ 4.43 (1.36 to 14.44)
*Linearmixed regression analysiswith time (inweeks)modeledwith ra
Cox regressionanalysis,withbaselinehazard functionmodeledwith4d
with a correct position and function of the prosthesis (less than grade
EuroSCORE the logistic EuroSCORE continuous; EuroSCORE20 t
of CA125; lnNT-proBNP natural logarithm of NT-proBNP; other abbrvolution after TAVI. Potentially, patients with rising levelsf CA125 after TAVI may be regarded to be at high risk for
vents and consequently may require close clinical observa-
ion and/or intensified treatment. At this moment, however,
t is unclear whether normalization of CA125 values by a more
ggressive treatment before and/or after TAVI, will attenuate
he elevated risk for adverse events. The answer to this question
ill require additional studies and, more importantly, clinical
rials specifically designed to address this issue.
Strength and limitations. First, this is the first to evaluate
he prognostic usefulness of CA125 in a novel setting
patients undergoing TAVI). Second, a novel statistical
pproach for modeling repeated measurements of CA125 is
mployed. This allowed us to monitor the follow-up of the
atients after TAVI with more statistical precision than
sing baseline values of the biomarker alone.
An inherent limitation of the JM analysis, we were not
ble to explore a more flexible functional form of CA125.
owever, our previous experience with CA125 in acute HF
upports the use of either linear or logarithmic transforma-
ion when related to the log hazard for all-cause mortality.
inally, some variables were missing during follow-up and
ere included in the longitudinal models with their baseline
alues.
onclusions
This study demonstrated for the first time that CA125 is an
eath MACE
I) p Value -Coefficient (95% CI) p Value
0.000 0.807 (0.272 to 1.343) 0.003
0.000 0.243 (0.185 to 0.301) 0.000
0.000 0.030 (0.045 to0.015) 0.000
0.043 0.128 (0.103 to 0.359) 0.276
2) 0.000 0.008 (0.016 to 0.001) 0.068
0.003 0.004 (0.001 to 0.009) 0.082
) 0.304 0.082 (0.173 to 0.337) 0.528
0.042 0.005 (0.001 to 0.010) 0.089
MACE
p Value HR (95% CI) p Value
0.043 2.26 (1.28 to 3.98) 0.005
0.659 0.95 (0.75 to 1.21) 0.691
0.028 1.15 (0.84 to 1.56) 0.380
0.016 0.48 (0.26 to 0.86) 0.015
0.014 4.78 (1.46 to 15.62) 0.010
tercept and slopes.†Time-varying.‡Baseline variable.§Parametric
of freedom–restricted cubic splines. Definedasprocedural success
al aortic regurgitation) and only 1 valve implanted per patient.
tic EuroSCORE dichotomized(20%); lnCA125 natural logarithm
s as in Tables 1 and 5.ause D
95% C
.004)
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496patients undergoing TAVI. Elevated pre-procedural and
the longitudinal evolution of CA125 levels predicted ad-
verse outcomes after TAVI.
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